Lv21
150 积分 2022-10-24 加入
Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline
6小时前
已完结
[Chinese expert consensus for molecular pathological diagnosis of gliomas (2025 version)]
7小时前
已完结
Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation
18天前
已关闭
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
18天前
已完结
NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
26天前
已完结
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study
26天前
已完结
P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS
26天前
已完结
Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face
3个月前
已完结
Phase II therapeutic equivalence study of Abiraterone Acetate Tablets (I) vs. ZYTIGA® in patients with metastatic castration-resistant prostate cancer
4个月前
已关闭
皖公网安备34019202002308
